353 related articles for article (PubMed ID: 27551012)
21. Overview of the therapeutic strategies for ER positive breast cancer.
Blakely B; Shin S; Jin K
Biochem Pharmacol; 2023 Jun; 212():115552. PubMed ID: 37068524
[TBL] [Abstract][Full Text] [Related]
22. ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.
Angus L; Beije N; Jager A; Martens JW; Sleijfer S
Cancer Treat Rev; 2017 Jan; 52():33-40. PubMed ID: 27886589
[TBL] [Abstract][Full Text] [Related]
23. Noninvasive detection of activating estrogen receptor 1 (ESR1) mutations in estrogen receptor-positive metastatic breast cancer.
Guttery DS; Page K; Hills A; Woodley L; Marchese SD; Rghebi B; Hastings RK; Luo J; Pringle JH; Stebbing J; Coombes RC; Ali S; Shaw JA
Clin Chem; 2015 Jul; 61(7):974-82. PubMed ID: 25979954
[TBL] [Abstract][Full Text] [Related]
24. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
25. Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
Yanagawa T; Kagara N; Miyake T; Tanei T; Naoi Y; Shimoda M; Shimazu K; Kim SJ; Noguchi S
Breast Cancer Res Treat; 2017 Jun; 163(2):231-240. PubMed ID: 28283903
[TBL] [Abstract][Full Text] [Related]
26. Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detection.
Cani AK; Dolce EM; Darga EP; Hu K; Liu CJ; Pierce J; Bradbury K; Kilgour E; Aung K; Schiavon G; Carroll D; Carr TH; Klinowska T; Lindemann J; Marshall G; Rowlands V; Harrington EA; Barrett JC; Sathiyayogan N; Morrow C; Sero V; Armstrong AC; Baird R; Hamilton E; Im SA; Jhaveri K; Patel MR; Dive C; Tomlins SA; Udager AM; Hayes DF; Paoletti C
Mol Oncol; 2022 May; 16(10):1969-1985. PubMed ID: 34866317
[TBL] [Abstract][Full Text] [Related]
27. ESR1 mutations in HR+/HER2-metastatic breast cancer: Enhancing the accuracy of ctDNA testing.
Venetis K; Pepe F; Pescia C; Cursano G; Criscitiello C; Frascarelli C; Mane E; Russo G; Taurelli Salimbeni B; Troncone G; Guerini Rocco E; Curigliano G; Fusco N; Malapelle U
Cancer Treat Rev; 2023 Dec; 121():102642. PubMed ID: 37864956
[TBL] [Abstract][Full Text] [Related]
28. Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant.
Spoerke JM; Gendreau S; Walter K; Qiu J; Wilson TR; Savage H; Aimi J; Derynck MK; Chen M; Chan IT; Amler LC; Hampton GM; Johnston S; Krop I; Schmid P; Lackner MR
Nat Commun; 2016 May; 7():11579. PubMed ID: 27174596
[TBL] [Abstract][Full Text] [Related]
29.
Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
[No Abstract] [Full Text] [Related]
30. Activating ESR1 mutations in hormone-resistant metastatic breast cancer.
Robinson DR; Wu YM; Vats P; Su F; Lonigro RJ; Cao X; Kalyana-Sundaram S; Wang R; Ning Y; Hodges L; Gursky A; Siddiqui J; Tomlins SA; Roychowdhury S; Pienta KJ; Kim SY; Roberts JS; Rae JM; Van Poznak CH; Hayes DF; Chugh R; Kunju LP; Talpaz M; Schott AF; Chinnaiyan AM
Nat Genet; 2013 Dec; 45(12):1446-51. PubMed ID: 24185510
[TBL] [Abstract][Full Text] [Related]
31. Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study.
Zivanovic Bujak A; Weng CF; Silva MJ; Yeung M; Lo L; Ftouni S; Litchfield C; Ko YA; Kuykhoven K; Van Geelen C; Chandrashekar S; Dawson MA; Loi S; Wong SQ; Dawson SJ
PLoS Med; 2020 Oct; 17(10):e1003363. PubMed ID: 33001984
[TBL] [Abstract][Full Text] [Related]
32. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
[TBL] [Abstract][Full Text] [Related]
33. Detection of Activating Estrogen Receptor Gene (
Paolillo C; Mu Z; Rossi G; Schiewer MJ; Nguyen T; Austin L; Capoluongo E; Knudsen K; Cristofanilli M; Fortina P
Clin Cancer Res; 2017 Oct; 23(20):6086-6093. PubMed ID: 28679775
[No Abstract] [Full Text] [Related]
34. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models.
Bahreini A; Li Z; Wang P; Levine KM; Tasdemir N; Cao L; Weir HM; Puhalla SL; Davidson NE; Stern AM; Chu D; Park BH; Lee AV; Oesterreich S
Breast Cancer Res; 2017 May; 19(1):60. PubMed ID: 28535794
[TBL] [Abstract][Full Text] [Related]
35. Preexisting Somatic Mutations of Estrogen Receptor Alpha (
Dahlgren M; George AM; Brueffer C; Gladchuk S; Chen Y; Vallon-Christersson J; Hegardt C; Häkkinen J; Rydén L; Malmberg M; Larsson C; Gruvberger-Saal SK; Ehinger A; Loman N; Borg Å; Saal LH
JNCI Cancer Spectr; 2021 Apr; 5(2):. PubMed ID: 33937624
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical analysis of estrogen receptor in breast cancer with ESR1 mutations detected by hybrid capture-based next-generation sequencing.
Ross DS; Zehir A; Brogi E; Konno F; Krystel-Whittemore M; Edelweiss M; Berger MF; Toy W; Chandarlapaty S; Razavi P; Baselga J; Wen HY
Mod Pathol; 2019 Jan; 32(1):81-87. PubMed ID: 30158597
[TBL] [Abstract][Full Text] [Related]
37. ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.
Jeselsohn R; Buchwalter G; De Angelis C; Brown M; Schiff R
Nat Rev Clin Oncol; 2015 Oct; 12(10):573-83. PubMed ID: 26122181
[TBL] [Abstract][Full Text] [Related]
38. Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer.
Patel JM; Jeselsohn RM
Adv Exp Med Biol; 2022; 1390():171-194. PubMed ID: 36107319
[TBL] [Abstract][Full Text] [Related]
39. Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.
Brett JO; Ritterhouse LL; Newman ET; Irwin KE; Dawson M; Ryan LY; Spring LM; Rivera MN; Lennerz JK; Dias-Santagata D; Ellisen LW; Bardia A; Wander SA
Oncologist; 2023 Feb; 28(2):172-179. PubMed ID: 36493359
[TBL] [Abstract][Full Text] [Related]
40. ESR1 mutations and therapeutic resistance in metastatic breast cancer: progress and remaining challenges.
Herzog SK; Fuqua SAW
Br J Cancer; 2022 Feb; 126(2):174-186. PubMed ID: 34621045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
